+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Osteonecrosis Treatment Market 2019-2023 - Product Image

Global Osteonecrosis Treatment Market 2019-2023

  • ID: 4704162
  • Report
  • November 2018
  • Region: Global
  • 116 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Atnahs
  • Merck Sharp & Dohme
  • Mylan
  • Pfizer
  • MORE
The introduction of cell therapy to boost the market growth. The development of stem cells is increasing to engineer advanced stem cells-based treatment that can demonstrate better efficacy and has fewer side effects than the available treatments. The analysts have predicted that the osteonecrosis treatment market will register a CAGR of more than 6% by 2023.

Market Overview

Rising awareness about osteonecrosis

Osteonecrosis is an idiopathic disease as it occurs without trauma and the early diagnosis increases the chances of treatment. Thus, an increasing awareness among people is expected to propel growth in the global osteonecrosis treatment market.

Availability of alternate therapies

The main aim after getting affected by any disease is to get the condition addressed as soon as possible to avoid the progress of osteonecrosis symptoms. Thus, the available treatment are expected to strongly decelerate the growth of the global osteonecrosis market.

For the detailed list of factors that will drive and challenge the growth of the osteonecrosis treatment market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Mylan and Pfizer the competitive environment is quite intense. Factors such as the rising awareness about osteonecrosis and the expansion of aircraft manufacturing facilities, will provide considerable growth opportunities to osteonecrosis treatment manufactures. Atnahs, Merck Sharp & Dohme, Mylan, Pfizer and Teva Pharmaceutical Industries are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Atnahs
  • Merck Sharp & Dohme
  • Mylan
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2028
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • NSAIDs - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Introduction of stem cell therapy
  • Strategic alliances
  • Increasing research for the diagnosis of osteonecrosis
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Atnahs
  • Merck Sharp & Dohme
  • Mylan
  • Pfizer
  • Teva Pharmaceutical Industries
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global rare disease drugs market
Exhibit 02: Segments of global rare disease drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: NSAIDs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: NSAIDs - Year-over-year growth 2019-2023 (%)
Exhibit 21: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in EMEA
Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in APAC
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Atnahs - Vendor overview
Exhibit 45: Atnahs - Organizational developments
Exhibit 46: Atnahs - Key offerings
Exhibit 47: Atnahs - Key customers
Exhibit 48: Atnahs - Key customers
Exhibit 49: Merck Sharp & Dohme - Vendor overview
Exhibit 50: Merck Sharp & Dohme - Business segments
Exhibit 51: Merck Sharp & Dohme - Organizational developments
Exhibit 52: Merck Sharp & Dohme - Geographic focus
Exhibit 53: Merck Sharp & Dohme - Key offerings
Exhibit 54: Merck Sharp & Dohme - Key customers
Exhibit 55: Mylan - Vendor overview
Exhibit 56: Mylan - Business segments
Exhibit 57: Mylan - Organizational developments
Exhibit 58: Mylan - Geographic focus
Exhibit 59: Mylan - Key offerings
Exhibit 60: Mylan - Key customers
Exhibit 61: Pfizer - Vendor overview
Exhibit 62: Pfizer - Business segments
Exhibit 63: Pfizer - Organizational developments
Exhibit 64: Pfizer - Geographic focus
Exhibit 65: Pfizer - Segment focus
Exhibit 66: Pfizer - Key offerings
Exhibit 67: Pfizer - Key customers
Exhibit 68: Teva Pharmaceutical Industries - Vendor overview
Exhibit 69: Teva Pharmaceutical Industries - Business segments
Exhibit 70: Teva Pharmaceutical Industries - Organizational developments
Exhibit 71: Teva Pharmaceutical Industries - Geographic focus
Exhibit 72: Teva Pharmaceutical Industries - Segment focus
Exhibit 73: Teva Pharmaceutical Industries - Key offerings
Exhibit 74: Teva Pharmaceutical Industries - Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Atnahs
  • Merck Sharp & Dohme
  • Mylan
  • Pfizer
  • MORE
Global Osteonecrosis Treatment Market 2019-2023

The author of the report recognizes the following companies as the key players in the global osteonecrosis treatment market: Atnahs, Merck Sharp & Dohme, Mylan, Pfizer and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the introduction of cell therapy.”

According to the report, one of the major drivers for this market is the rising awareness about osteonecrosis.

Further, the report states that one of the major factors hindering the growth of this market is the availability of alternate therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Atnahs
  • Merck Sharp & Dohme
  • Mylan
  • Pfizer
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
Adroll
adroll